BTAI (BioXcel Therapeutics) Inventory Turnover: 0.46 (As of Mar. 2026)


BTAI BioXcel Therapeutics Inc BTAI
8 GF Score
Price $0.82
GF Value $0.67
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is BioXcel Therapeutics Inventory Turnover?

BioXcel Therapeutics BTAI -2.42% 8 Inventory Turnover is 0.46 as of Mar. 2026. GuruFocus rates BTAI with a GF Score™ of 8/100 and a GF Value™ of $0.67 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. BioXcel Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2026 was $0.28 Mil. BioXcel Therapeutics's Average Total Inventories for the quarter that ended in Mar. 2026 was $0.61 Mil. BioXcel Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.46.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. BioXcel Therapeutics's Days Inventory for the three months ended in Mar. 2026 was 197.01.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. BioXcel Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 2.97.

BioXcel Therapeutics  (NAS:BTAI) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

BioXcel Therapeutics's Days Inventory for the three months ended in Mar. 2026 is calculated as:

Days Inventory =Average Total Inventories (Q: Mar. 2026 )/Cost of Goods Sold (Q: Mar. 2026 )*Days in Period
=0.611/0.283*365 / 4
=197.01

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

BioXcel Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=0.611 / 0.206
=2.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.

BioXcel Therapeutics Inventory Turnover Related Terms

BioXcel Therapeutics Inventory Turnover Historical Data

* Premium members only.

The historical data trend for BioXcel Therapeutics's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioXcel Therapeutics Inventory Turnover Chart

BioXcel Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventory Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.01 0.63 1.61 0.23

BioXcel Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.19 0.02 0.05 0.46
BTAI
8GF Score
BioXcel Therapeutics Inc BTAI
Inventory Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioXcel Therapeutics Inventory Turnover Calculation

BioXcel Therapeutics's Inventory Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Inventory Turnover (A: Dec. 2025 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Dec. 2025 ) / ((Total Inventories (A: Dec. 2024 ) + Total Inventories (A: Dec. 2025 )) / count )
=0.164 / ((0.679 + 0.722) / 2 )
=0.164 / 0.7005
=0.23

BioXcel Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2026 is calculated as

Inventory Turnover (Q: Mar. 2026 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Mar. 2026 ) / ((Total Inventories (Q: Dec. 2025 ) + Total Inventories (Q: Mar. 2026 )) / count )
=0.283 / ((0.722 + 0.5) / 2 )
=0.283 / 0.611
=0.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Inventory Turnover →
What does a Inventory Turnover of 0.46 mean?
BioXcel Therapeutics (BTAI) has a Inventory Turnover of 0.46 as of Mar. 2026. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on BioXcel Therapeutics and its competitors.
Is BioXcel Therapeutics' Inventory Turnover too high?
BioXcel Therapeutics' current Inventory Turnover is 0.46. Overall, BioXcel Therapeutics has a GF Score™ of 8/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioXcel Therapeutics' Inventory Turnover compare to IXHL and SCYX?
BioXcel Therapeutics' Inventory Turnover of 0.46 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventory Turnover for a Drug Manufacturers company?
A good Inventory Turnover depends on the Drug Manufacturers industry context. However, Inventory Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventory Turnover mean?
A high Inventory Turnover can signal that a stock is expensive relative to its fundamentals. Inventory turnover equals current-period cost of goods sold divided by average two-period total inventories. View historical data on BioXcel Therapeutics and its competitors. BioXcel Therapeutics's current Inventory Turnover is 0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioXcel Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, BioXcel Therapeutics (BTAI) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.67, compared to a current price of $0.82 — trading 22.1% above its estimated fair value. The current Inventory Turnover is 0.46. BioXcel Therapeutics' overall GF Score™ is 8/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventory Turnover calculated?
Inventory Turnover is calculated from a company's financial statements. For BioXcel Therapeutics (BTAI), the current Inventory Turnover is 0.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioXcel Therapeutics (BTAI) Overvalued in 2026?

Based on GuruFocus' analysis, BioXcel Therapeutics stock appears to be overvalued. The current stock price of $0.82 is trading 22.1% above its estimated GF Value™ of $0.67. GuruFocus considers BioXcel Therapeutics to be Modestly Overvalued.

Key valuation signals for BTAI:

  • Inventory Turnover: 0.46
  • GF Value™: $0.67 vs. price of $0.82 (22.1% above fair value)
  • GF Score™: 8/100 with 5 warning signs

No single metric tells the full story. See the BTAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioXcel Therapeutics Business Description

Other Exchanges BX20:Germany
Address 555 Long Wharf Drive, New Haven, CT, USA, 06511
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
8GF Score

Get the complete analysis for BTAI

Inventory Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.82
Price
$0.67
GF Value